Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Journal Information
Full Title: JAMA Neurol
Abbreviation: JAMA Neurol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Evidence found in paper:
"US Department of Education and National Institute on Disability, Independent Living, and Rehabilitation Research; US Department of Defense; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Parent Project Muscular Dystrophy; NS Pharma"
Protocol Registration
Evidence found in paper:
"Trial Registration ClinicalTrials.gov Identifier: NCT02740972"
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025